Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Replimune Group, Inc. - Common Stock (NQ: REPL )

12.50 +0.16 (+1.30%)
Streaming Delayed Price Updated: 1:00 PM EST, Dec 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 329,481
Open 12.21
Bid (Size) 12.12 (80)
Ask (Size) 13.59 (2)
Prev. Close 12.34
Today's Range 12.12 - 12.59
52wk Range 4.920 - 17.00
Shares Outstanding 46,772,263
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Replimune to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Replimune Group Inc
Via GlobeNewswire
Replimune Announces Pricing of Upsized Public Offering
From Replimune Group Inc
Via GlobeNewswire

Performance

YTD
+44.18%
+44.18%
1 Month
-5.73%
-5.73%
3 Month
+12.92%
+12.92%
6 Month
+43.51%
+43.51%
1 Year
+53.94%
+53.94%

More News

Read More
Replimune Announces Proposed Public Offering
From Replimune Group Inc
Via GlobeNewswire
Replimune Group: Q3 Earnings Insights
Via Benzinga
Barclays Maintains Overweight Rating for Replimune Group: Here's What You Need To Know
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
S&P 500 Moves Higher; Intuit Shares Fall Following Q1 Results
Via Benzinga
Topics Stocks
Exposures US Equities
Crude Oil Gains Over 1%; Ross Stores Earnings Top Views
Via Benzinga
Exposures Fossil Fuels
Natural Grocers By Vitamin Cottage, Elastic, Matthews International, Gap And Other Big Stocks Moving Higher On Friday
Via Benzinga
Dow Jumps 300 Points; Gap Posts Upbeat Earnings
Via Benzinga
Topics Stocks
Exposures US Equities
Replimune Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway
From Replimune Group Inc
Via GlobeNewswire
Replimune Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update
From Replimune Group Inc
Via GlobeNewswire
Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)
From Replimune Group Inc
Via GlobeNewswire
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Replimune Group Inc
Via GlobeNewswire
Replimune to Present at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
From Replimune Group Inc
Via GlobeNewswire
REPL Stock Earnings: Replimune Group Beats EPS for Q1 2025
Via InvestorPlace
Vail Resorts Posts Downbeat Q3 Results, Joins Concrete Pumping, DocuSign And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
S&P 500 Edges Lower; J. M. Smucker Shares Surge Following Earnings Beat
Via Benzinga
Topics Stocks
Exposures US Equities
Why G-III Apparel Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Crude Oil Jumps 2%; Lululemon Posts Upbeat Earnings
Via Benzinga
Exposures Fossil Fuels
Why Is Mid-Cap Cancer-Focused Replimune Stock Trading Higher On Thursday?
Via Benzinga
J.M. SmuckerPosts Upbeat Earnings, Joins Toro Company, United Natural Foods, Semtech And Other Big Stocks Moving Higher On Thursday
Via Benzinga
REPL Stock Earnings: Replimune Group Misses EPS for Q4 2024
Via InvestorPlace
Crude Oil Moves Lower; AutoZone Profit Tops Views
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.